The canonical role of messenger RNA (mRNA) is to deliver protein-coding information to sites of protein synthesis. However, given that microRNAs bind to RNAs, we hypothesized that RNAs could possess a regulatory role that relies on their ability to compete for microRNA binding, independently of their protein-coding function. As a model for the protein-coding-independent role of RNAs, we describe the functional relationship between the mRNAs produced by the PTEN tumour suppressor gene and its pseudogene PTENP1 and the critical consequences of this interaction. We find that PTENP1 is biologically active as it can regulate cellular levels of PTEN and exert a growth-suppressive role. We also show that the PTENP1 locus is selectively lost in human cancer. We extended our analysis to other cancer-related genes that possess pseudogenes, such as oncogenic KRAS. We also demonstrate that the transcripts of protein-coding genes such as PTEN are biologically active. These findings attribute a novel biological role to expressed pseudogenes, as they can regulate coding gene expression, and reveal a non-coding function for mRNAs.
In human cancers, monoallelic mutation of PTEN without loss or mutation of the second allele is prevalent at presentation, whereas complete loss is observed at low frequencies with the exception of advanced cancers 1 . In mouse models, heterozygosity for Pten leads to multiple cancers 2 , and serial reduction of Pten dosage has critical consequences for the incidence and severity of epithelial cancers 3, 4 , together indicating that PTEN is a functionally haploinsufficient tumour suppressor gene. The identification and validation of numerous PTEN-targeting microRNAs (miRNAs) demonstrates that posttranscriptional regulation has a pivotal role in determining PTEN abundance in cancer cells [5] [6] [7] [8] [9] [10] [11] . Cells are ultrasensitive to even subtle decreases in PTEN abundance, thus highlighting the importance of miRNA-mediated PTEN regulation in cancer 4 . Therefore, we reasoned that the relationship between PTEN and its pseudogene PTENP1 (also called PTH2 or yPTEN) 12 could represent a compelling test for our hypothesis (Fig. 1a ).
Pseudogenes are defined as genomic loci that resemble real genes, yet are considered to be biologically inconsequential because they harbour premature stop codons, deletions/insertions and frameshift mutations that abrogate their translation into functional proteins. Nevertheless, nucleotide sequences contained within pseudogenes are well preserved, suggesting that selective pressure to maintain these genetic elements exists, and that they may indeed have an important cellular role.
Pseudogenes exist as either processed or non-processed genetic elements. Although non-processed pseudogenes arose from genetic duplications, processed pseudogenes were generated through retrotransposition; thus, they contain no introns yet they commonly share 59 and 39 untranslated region (UTR) sequences with their ancestral genes 13 . Pseudogenes are almost as numerous as coding genes and represent a significant proportion of the 'transcriptome' 14 . Despite lacking canonical promoters, processed pseudogenes use proximal regulatory elements to mediate their transcription 15 . Pseudogene transcription exhibits tissue-specificity 16 and is aberrantly activated in cancer 17 , indicating that pseudogenes may contribute to carcinogenesis, although the mechanisms still remain elusive. Very few pseudogenes have been functionally characterized thus far 13 . miRNAs, a large class of small non-coding RNAs, have emerged as a critical element in cellular biology and pathophysiology, and have been demonstrated to have an impact on almost all cellular processes and cell types from plants to humans 18 . miRNAs function by annealing to complementary sites on coding sequences or 39 UTRs of target gene transcripts, where they promote the recruitment of protein complexes that impair translation and/or decrease the stability of mRNA, leading to a decrease in target protein abundance [18] [19] [20] [21] . Physiologically, aberrant expression of miRNAs has been causally linked to human diseases and cancer 22 .
We have tested whether pseudogene-derived RNA transcripts and mRNA transcripts possess an active biological role in cancer that is independent of their protein-coding function but would rely upon their ability to compete for miRNA binding, thereby modulating the derepression of miRNA targets ( Fig. 1a ).
PTENP1 is targeted by PTEN-targeting miRNAs PTENP1 is a processed pseudogene located at 9p13.3; it is highly homologous to PTEN, with only 18 mismatches throughout the coding sequence. A missense mutation of the initiator methionine codon prevents translation 12 . PTENP1 possesses a 39 UTR that is ,1 kilobase shorter than that of PTEN ( Fig. 1b ). It can be divided into two regions relative to its homology with the PTEN 39 UTR: a high homology (,95%) 59 region and a low homology (,50%) 39 region ( Fig. 1b and Supplementary Fig. 1 ). Within the high homology *These authors contributed equally to this work. region, we found perfectly conserved seed matches for the PTENtargeting miR-17, miR-21, miR-214, miR-19 and miR-26 families ( Fig. 1c and Supplementary Fig. 1 ). To measure the function of these miRNAs on both PTEN and PTENP1 expression, we designed specific PCR primer sets in the non-homologous 39 UTR regions ( Supplementary Fig. 2a, b ). In DU145 prostate cancer cells, PTENtargeting miRNAs miR-19b and miR-20a suppressed both PTEN and PTENP1 mRNA abundance ( Fig. 1d and Supplementary Fig. 3a ). In these cells, a pool of inhibitors of endogenously expressed PTENtargeting miRNAs ( Supplementary Fig. 3b ) derepressed both PTEN and PTENP1 transcript levels (Fig. 1e ). The use of chimaeric luciferase plasmids indicated that the miRNA-PTENP1 interaction was direct ( Supplementary Fig. 4a -c). These data indicate that PTENP1 and PTEN are subjected to the same miRNA-mediated, posttranscriptional regulation.
The 39 UTR of PTENP1 has tumour suppressive activity We examined the ability of PTENP1 39 UTR to function as a decoy of PTEN-targeting miRNAs using a retroviral vector expressing this 39 UTR ( Supplementary Fig. 5a ). The 39 UTR can be transcribed, but it cannot code for protein; however, it still may exert a biological role. Indeed, PTENP1 39 UTR overexpression resulted in a derepression of both PTEN transcript and protein ( Fig. 2a and Supplementary Figs 5b  and 10c ). Consistent with elevated PTEN, AKT phosphorylation was reduced upon stimulation of cells with EGF ( Fig. 2b) . These molecular observations were accompanied by growth inhibition ( Fig. 2c and Supplementary Figs 5c and 10d ) and a significant reduction in the number of colonies generated in semisolid medium (Fig. 2d ).
The derepression of PTEN abundance by PTENP1 39 UTR overexpression was blunted in HCT116 DICER 2/2 colon carcinoma cells ( Fig. 2e ). In these cells, the disruption of DICER-the enzyme that catalyses the last step of miRNA maturation-leads to reduced levels of mature miRNAs compared to parental HCT116 cells 23 . This in turn supports the notion that the 39 UTR of PTENP1 requires mature miRNAs for its function towards PTEN.
To examine the phenotypic consequences of PTENP1 downregulation, we designed custom small interfering RNA (siRNA) pools (Dharmacon) to target specifically either PTENP1 (si-PTENP1) or PTEN (si-PTEN) expression ( Supplementary Fig. 6 ) because commercially available siRNA pools for PTEN (si-PTEN/PTENP1) bind to common sequences in PTEN and PTENP1 ( Supplementary  Fig. 7a ). si-PTENP1 transfection accelerated cell proliferation, indicating that PTENP1, although expressed at lower relative levels, can exert a biological activity in DU145 cells ( Fig. 2f ). si-PTEN/PTENP1, which silences both PTEN and PTENP1, showed the strongest effect, indicating that PTEN and its pseudogene may have additive roles for growth suppression. PTENP1 knockdown resulted in decreased PTEN mRNA and protein abundance ( Fig. 2g , h), mirroring the results obtained with overexpression of PTENP1 39 UTR ( Fig. 2a ).
In DU145 cells PTENP1 39 UTR is a more potent growth suppressor compared to PTEN ( Fig. 2d and Supplementary Fig. 5c ). This result may be explained by the fact that miRNAs for which PTENP1 functions as a decoy also bind other targets with tumour suppressive activities. For instance, the miR-17 family targets E2F1 and p21 24 , and miR-21 targets PDCD4 25 . Accordingly, miR-17 and miR-21 mimics increase proliferation of PTEN-null PC3 cells (Supplementary Fig. 8a ), indicating PTEN independency. Indeed, si-PTENP1 resulted in a dose-dependent downregulation not only of PTEN but also of p21 ( Supplementary Fig. 8b ). Additionally, both si-PTENP1 and si-PTEN/PTENP1 were able to suppress PTENP1 and increase proliferation in a dose-dependent manner in PTEN-null PC3 cells ( Supplementary Fig. 8c, d ). Conversely, stable infection of PTENP1 39 UTR in PC3 cells suppressed foci formation (Supplementary Fig. 8e ), supporting the notion that PTENP1 and its 39 UTR exert a tumour suppressive role that goes beyond the regulation of PTEN abundance alone.
Expression and losses of PTENP1 in human cancer PTEN and PTENP1 expression was explored in normal human tissues and prostate tumour samples, using custom Taqman probes (see Methods and Supplementary Fig. 2c ). In both the normal tissue and prostate tumour samples, the direct correlation (r 5 0.8087, P , 0.0001 and r 5 0.7538, P , 0.0001, respectively) between PTEN and PTENP1 expression suggests that they may be co-regulated ( Fig. 3a, b ). This finding supports our molecular observations that PTENP1 can regulate PTEN expression. PTENP1 was found to be variably abundant, and in some cases expressed at higher levels than PTEN.
Next, we examined alterations of the PTENP1 genomic locus. Several array-based databases were mined including The Cancer Workbench (https://cgwb.nci.nih.gov/cgi-bin/heatmap) and NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) ( Supplementary Fig. 9a , b and Supplementary Table 1 ). Remarkably, in a data set of sporadic colon cancer (http://www.ncbi.nlm.nih.gov/projects/geo/query/ acc.cgi?acc5GSE16125) ( Fig. 3c-e ), hierarchical clustering identified a clear population of samples with detectable copy number losses occurring specifically at the PTENP1 locus ( Fig. 3c ). Notably, these copy number losses were focal, not associated with large losses of 9p, and independent of losses at the CDKN2A locus ( Supplementary  Fig. 9c ). This data set formally demonstrates the existence of independent genomic copy number losses at the PTENP1 locus, supporting the notion that PTENP1 exerts tumour suppressive functions and is under selective pressure to undergo copy number losses in cancer. 
5′ miR-214 2 6 2 6 2 6 2 1 2 1 6 1 7 1 9 1 9 1 9 2 1 4 2 1 7 1.5 In the same patient sample set, cluster analysis of PTEN expression showed that it was downregulated compared to normal colon samples (P 5 0.0008156; Fig. 3d ). Regression analysis of PTENP1 copy number variation with the expression levels of PTEN identified two discrete populations of patients in which PTENP1 copy number variation and PTEN expression were directly and significantly correlated (population 1: r 5 0.6105, P 5 0.0092; population 2: r 5 0.6056, P 5 0.0129) (Fig. 3e ). The existence of a direct relationship between PTENP1 copy number and PTEN expression supports our hypothesis that PTENP1 transcript levels can regulate PTEN expression. Together, these findings constitute a proof of principle for the oncosuppressive activity of PTENP1.
A general model for endogenous mRNA-mediated biology On the basis of our results, we expected that the PTEN 39 UTR would also have biological activity. Indeed, we found that PTEN 39 UTR can derepress PTENP1 abundance, as PTENP1 does on PTEN (Fig. 4a , left and Supplementary Fig. 10a-c) . Importantly, PTEN 39 UTR overexpression was accompanied by growth inhibition, suggesting that PTEN exerts its tumour suppressive activity, at least in part, through its 39 UTR (Fig. 4a, right and Supplementary Fig. 10d ).
To extend our studies beyond PTEN and its pseudogene, we examined other cancer-related pseudogenes and genes (Supplementary Tables 2 and 3 and Supplementary Figs 11-17 ). Alignments of gene and pseudogene sequences show that miRNA-binding sites are well conserved: for example, the miR-145 binding site on OCT4 (also called POU5F1) and its pseudogenes OCT4-pg1, OCT4-pg3, OCT4-pg4 and OCT4-pg5 (also called POU5F1P1, POU5F1P3, POU5F1P4 and POU5F1P5, respectively; Supplementary Fig. 11a ); miR-1 family binding sites on connexin 43 (CX43, also called GJA1) and its pseudogene ( Supplementary Fig. 11b ). Notably, OCT4-pg1 and OCT4-pg5 are exclusively expressed in cancer tissues and not in normal tissues 17 . Furthermore OCT4-pg5 is truncated at the 59 end and expresses only a partial open reading frame region followed by the 39 UTR 26 . Further examples of such conservation include: miR-34 family binding site on CDK4PS ( Supplementary Fig. 12 ); miR-182 binding site on FOXO3B ( Supplementary Fig. 13 ); miR-17 family binding site on E2F3P1 ( Supplementary Fig. 14) ; and miR-143 and let-7 family binding sites on KRAS1P ( Supplementary Fig. 15 ).
Because the 39 UTR of PTENP1 was growth suppressive like its parental gene PTEN, we hypothesized a similar relationship between KRAS and its pseudogene KRAS1P. Indeed, KRAS1P 39 UTR overexpression in DU145 cells resulted in increased KRAS mRNA abundance (Fig. 4b, left and Supplementary Fig. 18a, b ) and accelerated cell growth (Fig. 4b, right ). We also found that the KRAS and KRAS1P transcript levels are positively correlated in prostate cancer (Supplementary Fig. 18c) . Notably, the KRAS1P locus at 6p11-12 is amplified in different human tumours, including neuroblastoma, retinoblastoma and hepatocellular carcinoma [27] [28] [29] . Together these findings point to a putative proto-oncogenic role for KRAS1P, and support the notion that pseudogene functions mirror the functions of their cognate genes as explained by a miRNA decoy mechanism.
Discussion
The findings presented in this study have allowed us to reach a number of conclusions. First, the discovery of an miRNA decoy function for pseudogenes identifies these transcripts as biologically active units. We show that PTENP1 and KRAS1P affect the levels of their cognate genes and are possibly involved in disease pathogenesis. Thus, the analysis of pseudogene expression level and genomic status in tumorigenesis needs to be undertaken systematically to further our understanding of disease progression. Processed pseudogenes in mouse oocytes have been previously reported to generate endogenous siRNAs (endo-siRNAs) that downregulate the expression of cognate genes through conventional RNA interference 30 . However, endo-siRNA production has yet to be identified in somatic human cells 31 . Notably, although only few pseudogenes undergo antisense transcription, all transcribed pseudogenes can in principle compete with cognate genes for miRNA binding. Similarly, the miRNA decoy capacity of pseudogenes is likely to be more widespread than their cleavage into Piwi-interacting RNAs (piRNAs), which have been recently discovered only in germ cells of many organisms, including mouse 32 .
We also demonstrate that pseudogenes such as PTENP1 can derepress their cognate genes, even when expressed at lower levels ( Supplementary Fig. 3a and Fig. 2f-h) . We propose that pseudogenes are 'perfect decoys' for their ancestral genes, because they retain many of the miRNA binding sites and can compete for the binding of many miRNAs at once. It has been hypothesized that suboptimal 'pseudotargets' may compete with authentic targets for miRNA binding 33 . By contrast, we propose that pseudogenes have an intrinsic biological activity in miRNA networks because they are legitimate miRNA targets and compete with other legitimate targets for miRNA binding (Fig. 2e ). This notion is corroborated by the 'target mimicry' process 102770  D12  748  8540  350  E8  E2  E2  D6  C11  E3  D8  D5  C10  E1  D7  10866  D3  E11  D10  D4  D9  F12  C12  E7  E4  2040  D11  D1  12239  F11  E10  E6  F8  E12  D2  E5  F6  C8  C5  F1  C4  11901  C9  C3  F7  C7  C1  E9  F10  20731  107974  F3  117782  F5  C2  106424  108220  106623  C6 that in plants is achieved by the expression of non-protein coding genes that sequester miRNAs 34 . Exogenously administered miRNA sponges have recently emerged as effective and specific inhibitors of miRNAs 35, 36 . Pseudogenes act like 'endogenous competitors', able to affect the distribution of miRNA molecules on all their targets. They may be particularly effective precisely because they are non-coding, thus active translation does not interfere with miRNA binding 37 .
The ability of pseudogenes to regulate the biology of a cell goes beyond their ability to modulate the levels of their cognate gene ( Supplementary Fig. 8 ). This phenomenon is consistent with the fact that each miRNA has multiple targets and can lead to widespread homeostatic effects. Also, given that a single gene often has numerous differentially regulated pseudogenes (for example, OCT4, NPM1 ( Supplementary Figs 11a and 17 ) and ribosomal protein pseudogenes 38 ), such networks can become intricately dynamic.
Cellular miRNA abundance is dictated by total genomic copy number and by their biogenesis process 39 . Less is known about the regulation of mature miRNA activity. miRNAs can increase their spectrum of targetable mRNAs by undergoing deamination 40 , whereas shortening of 39 UTRs 41 and polymorphisms can prevent miRNA binding to mRNAs 42 . Pseudogene-mediated miRNA decoys offer a new dimension regulating the cross-talk between miRNAs and their targets. Indeed, the greater the number of pseudogenes that a protein-coding gene has, the more it is protected from miRNAs.
Our discovery of a functional role for PTENP1 is relevant to PTEN biology as minute changes in PTEN can have tumorigenic consequences 3 . In our analysis we found that PTENP1 positively regulates PTEN levels. Furthermore, we found that the PTENP1 locus undergoes copy number losses in human cancer and this correlates with a decrease in PTEN; thus we propose that PTENP1 is a bona fide tumour suppressor gene. In light of this, better tools must be developed to detect pseudogene abundance in cancer. For instance, pseudogenes including PTENP1 have been overlooked to such an extent that pseudogene-specific probes are absent in some microarray platforms ( Supplementary Fig. 7b ).
An important implication of our findings is that the decoy mechanism may not be limited to pseudogenes, but may include other long non-coding RNA transcripts including ribosomal RNAs, large intergenic noncoding RNAs (lincRNAs) and coding gene mRNAs 38, 43 ( Fig. 4a and Supplementary Fig. 10 ). Beyond their function as cis regulatory elements that impact the stability of their own transcripts, UTRs are also trans modulators of gene expression through miRNA binding. Furthermore, as binding sites for miRNAs are also located in open reading frame sequences 20 , the entire transcript of coding genes, and not only the 39 UTR, may possess decoy function (see working model, Fig. 4c ).
As our model suggests, mRNA introduced into a cell can potentially perturb the interaction between miRNAs and their multiple targets and thus have a biological activity independent of the translation of the protein they encode 44 . Notably, the same applies to the transcriptional induction or repression of endogenous mRNA levels, which can lead to changes in the number of mRNA molecules present within a cell in the scale of several orders of magnitude 45 .
Our findings indicate that when studying specific nonsense or frameshift mutations and genomic alterations leading to 'readthrough' or fusion transcripts one must consider this new RNAregulated biological dimension. For example, chromosomal fusion events such as the t(15;17) translocation of APL which generates PML-RARa and RARa-PML fusion transcripts or recurrent readthrough transcripts in melanoma such as CDK2-RAB5B could exert oncogenic activities through aberrant competition for microRNAs 46, 47 . This phenomenon could also occur as a consequence of somatic genomic rearrangements, which are emerging as grossly unappreciated events in many cancers 48 . Moreover, the shortening of 39 UTRs as observed in human cancer cells 41 would not solely affect miRNAdependent regulation but also alter the 'competing' capacity of a given RNA transcript. Finally, in the case of PTEN-loss-associated cancers, little is known of the molecular consequences of PTEN mutations where the PTEN transcript is retained, compared to complete genetic loss of PTEN where no transcript remains 1 . Although these events were previously thought to alter protein abundance, protein signalling and protein networks, they will also have a significant impact on cellular RNA and miRNA homeostasis. We have therefore identified a novel dimension by which cellular and tumour biology can be regulated.
METHODS SUMMARY
Cell lines were cultured under standard conditions. miRNA overexpression was obtained by transient transfection (si-miRNAs). PTENP1/PTEN/KRAS1P 39 UTR overexpression was achieved by transient transfection (pCMV expression vectors) or stable infection with MSCV-PIG retroviral constructs. miRNAtarget interaction was measured by luciferase reporter assay. PTENP1, PTEN, KRAS, KRAS1P and miRNA expression level was detected by real-time PCR. Proliferation, foci and soft agar assays were performed according to standard protocols.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. In the steady state (middle), equilibrium exists between the miRNA molecules and their targets X and Y. Downregulation of X (left) leads to increased availability of miRNA molecules to bind to Y, thus decreasing its abundance. By contrast, overexpression of X (right) leads to fewer miRNA molecules free to bind to Y, and thus Y abundance increases. Red rectangles, miRNA molecules. X and Y can be a pseudogene and its cognate proteincoding gene. Data in a and b indicate mean 6 s.d., n $ 3. *P , 0.05; ***P , 0.001. NATURE | Vol 465 | 24 June 2010
